AB
ORIC icon

Amalgamated Bank’s Oric Pharmaceuticals ORIC Stock Holding History

Amalgamated Bank’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,078
Closed -$17K – 2464
2025
Q4 		$17K Sell
2,078
-52
-2% -$599 ﹤0.01% 2187
2025
Q3 		$26K Hold
2,130
– – ﹤0.01% 2023
2025
Q2 		$22K Hold
2,130
– – ﹤0.01% 2077
2025
Q1 		$12K Hold
2,130
– – ﹤0.01% 2295
2024
Q4 		$17K Hold
2,130
– – ﹤0.01% 2188
2024
Q3 		$22K Hold
2,130
– – ﹤0.01% 2098
2024
Q2 		$15K Buy
2,130
+814
+62% +$7.29K ﹤0.01% 2241
2024
Q1 		$18K Sell
1,316
-2,089
-61% -$24.8K ﹤0.01% 2174
2023
Q4 		$31K Sell
3,405
-392
-10% -$2.83K ﹤0.01% 2447
2023
Q3 		$23K Hold
3,797
– – ﹤0.01% 2589
2023
Q2 		$29K Buy
+3,797
New +$21.6K ﹤0.01% 2551
2022
Q2 		– Sell
-4,028
Closed -$22K – 3153
2022
Q1 		$22K Buy
+4,028
New +$36.3K ﹤0.01% 2779

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Amalgamated Bank's ORIC Position: Q1 2026 in Review

Amalgamated Bank sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 2,078 shares — an estimated $17K sold.

Amalgamated Bank first reported a position in ORIC in Q1 2022 and held it in 12 quarters. The position peaked at $31K in Q4 2023. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Amalgamated Bank reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,078 Oric Pharmaceuticals shares in Q1 2026, an estimated $17K.
  • Amalgamated Bank first reported a position in Oric Pharmaceuticals in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's Oric Pharmaceuticals position peaked at $31K in Q4 2023.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.